Skip to content
2000
Volume 19, Issue 22
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Abnormal regulation of the ubiquitin-proteasome system (UPS) has been known to be involved in the pathogenesis of a variety of human diseases. A number of studies have focused on the identification of small modifiers for the UPS. Even though the proteasome inhibitor Bortezomib (Velcade®) has been approved for the therapy of multiple myeloma and mantle cell lymphoma, there are still no DUB inhibitors endorsed for clinical usage. Since deubiquitinating enzymes (DUBs) are becoming as a new class of modifiers in the UPS, potential drugs that target specific DUBs have been investigated with the development of experimental technologies for screening small inhibitor molecules. However, the molecular mechanisms of these molecules are poorly understood. In order to design and develop specific small inhibitor molecules for specific DUBs, identification of specific substrates and molecular structures for each DUB is required. Here, we review structures, substrates, and small inhibitor molecules of DUBs identified up to date, providing a clear rationale for the development of novel small inhibitor molecules of DUBs for cancer.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612811319220013
2013-07-01
2025-06-12
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612811319220013
Loading

  • Article Type:
    Research Article
Keyword(s): Deubiquitination; Inhibitor; JAMM; Josephin; OTU; UCH; USP
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test